Advertisement

Topics

Selumetinib Fails to Improve Outcomes With Dacarbazine in Uveal Melanoma

01:00 EDT 20 Mar 2018 | Cancer Networks

The combination of selumetinib with dacarbazine did not offer improved survival outcomes over placebo/dacarbazine in patients with metastatic uveal melanoma.

Original Article: Selumetinib Fails to Improve Outcomes With Dacarbazine in Uveal Melanoma

NEXT ARTICLE

More From BioPortfolio on "Selumetinib Fails to Improve Outcomes With Dacarbazine in Uveal Melanoma"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Melanoma
Melanoma is a highly malignant tumor of melanin-forming cells (melanocytes) There are most commonly found in the skin (resulting from sunlight exposure), but also in the eyes and mucous membranes. Metastasis to other regions of the body is also common....